Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082795 | 0.84 | PBK (0.49) | NAMPTKMT2ACYP3A4PBKSMO | |
| SCHEMBL14082282 | 0.81 | CYP3A4 (0.61) | NAMPTKMT2ACYP3A4MEN1QPCT | |
| SCHEMBL21857890 | 0.81 | CYP3A4 (0.70) | NAMPTKMT2ACYP3A4MEN1QPCT | |
| SCHEMBL14082584 | 0.81 | NAMPT (0.59) | NAMPTKMT2ACYP3A4MEN1QPCT | |
| SCHEMBL14082119 | 0.81 | HIF1A (0.70) | NAMPTTRPV1 | |
| SCHEMBL1394015 | 0.81 | NAMPT (0.70) | NAMPTKMT2ACYP3A4MEN1QPCT | |
| SCHEMBL14082114 | 0.79 | TRPV1 (0.56) | KMT2AMEN1TRPV1 | |
| SCHEMBL14082121 | 0.78 | TRPV1 (0.58) | KMT2AMEN1TRPV1 | |
| SCHEMBL19303133 | 0.78 | KMT2A (0.67) | NAMPTKMT2ACYP3A4MEN1QPCT | |
| SCHEMBL5553234 | 0.77 | KMT2A (0.63) | NAMPTKMT2ACYP3A4MEN1QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | NAMPT 1183/4885KMT2A 4272/4885CYP3A4 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.